This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Prostate cancer	Lysine-specific demethylase 4A (KDM4A; JMJD2A); KDM4B (JMJD2B)	Cell culture studies suggest inhibiting KDM4A and KDM4B could help treat prostate cancer. In human prostate cancer cell lines, shRNA knockdown of <i>KDM4A</i> or <i>KDM4B</i> increased apoptosis compared with no alteration. In a human prostate cancer cell line, a KDM4A and KDM4B inhibitor decreased proliferation compared with no treatment and downregulated expression of androgen receptor-responsive genes. Next steps include developing optimized derivatives of the lead KDM4A and KDM4B inhibitor for treatment of prostate cancer.	Provisional patent application filed; unavailable for licensing	Chu, C.-H. <i>et al. J. Med. Chem.</i> ; published online June 27, 2014; doi:10.1021/jm500249n Contact: Wen-Ching Wang, National Tsing-Hua University, Hsinchu, Taiwan e-mail: wcwang@life.nthu.edu.tw Contact: Hsing-Jien Kung, University of California, Davis Comprehensive Cancer Center, Sacramento, Calif. e-mail: hkung@nhri.org.tw
		<i>SciBX</i> 7(32); doi:10.1038/scibx.2014.951 Published online Aug. 21, 2014		